Unlike the USA, Great Britain Takes Avandia Off the Shelf

Unlike the US FDA, British regulators have ruled that GlaxoSmithKline’s diabetes drug Avandia could lead to heart attacks or strokes, and benefits no longer outweigh the risks. And so last week, they told 90,000 British diabetes patients to stop taking it.

Evidence linking Avandia to an increased risk of a heart attack or stroke has been building since 2007, and GSK has agreed to pay $460 million in damages to settle about 10,000 lawsuits in America linking its use to patients suffering serious medical setbacks. But the FDA has chosen only to monitor the drug, rather than ask for a recall.

Post your comment